UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13G
                    Under the Securities Exchange Act of 1934

                                Amendment No.: 2

                    Name of Issuer: DUSA PHARMACEUTICALS INC.

             Title of Class of Securities: COMMON STOCK NO PAR VALUE

                             CUSIP Number: 266898105



 Check the appropriate box to designate the rule pursuant to which this
                               Schedule is filed:
                                [x] Rule 13d-1(b)
                                [ ] Rule 13d-1(c)
                                [ ] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).

1.     Name of Reporting Person and S.S. or I.R.S. Identification
        No of Above Person:    Pequot Capital Management, Inc.
        Tax ID:                          06-1524885

2.     Check the Appropriate Box if a Member of a Group
        a.
        b.

3.     SEC Use Only

4.     Citizenship or Place of Organization:
        Connecticut

Number of Shares Beneficially Owned by Each Reporting Person With:

       5.     Sole Voting Power:     203,800

       6.     Shared Voting Power:     0

       7.     Sole Dispositive Power:  203,800

       8.     Shared Dispositive Power:     0

9.     Aggregate Amount Beneficially Owned by Each Reporting Person:
       203,800

10.    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:

11.    Percent of Class Represented by Amount in Row (9):    1.47%

12.    Type of Reporting Person:     IA, CO


Item 1(a)         Name of Issuer:  DUSA PHARMACEUTICALS INC.

     1(b)         Address of Issuer's Principal Executive Offices:
                  25 Upton Drive, Wilmington, Massachusetts 01887

Item 2(a)-(c)    Name, Principal Business Address, and Citizenship of Persons
                 Filing:
                 Pequot Capital Management, Inc., 500 Nyala Farm Road, Westport,
                 CT, 06880, which is a Connecticut corporation.

     (d) Title of Class of Securities: COMMON STOCK NO PAR VALUE

     (e)          CUSIP Number: 266898105

Item 3.  This statement is filed pursuant to Rule 13d-1(b)(1)(ii)(E).
         Pequot Capital Management, Inc. is an investment adviser registered
                  under Section 203 of the Investment Advisers Act of 1940.

Item 4.  Ownership.
         Ownership as of February 28, 2002 is incorporated by reference to items
                  (5) - (9) and (11) of the cover page of the reporting person.

Item 5.  Ownership of Five Percent or Less of a Class.
         If this statement is being filed to report the fact that as of the date
         hereof the reporting person has ceased to be the beneficial owner of
         more than five percent of the class of securities, check the following.

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.
                  Not applicable.

Item 7.  Identification and Classification of the Subsidiary Which Acquired the
         Security Being Reported by the Parent Holding Company.
         Not applicable

Item 8.  Identification and Classification of Members of the Group.
         Not applicable

Item 9.  Notice of Dissolution of the Group.
         Not applicable

Item 10.

By signing below, I certify that, to the best of my knowledge and belief, the
Securities referred to above were acquired in the ordinary course of business
and were not acquired for the purpose and do not have the effect of changing or
influencing the control of the issuer of such securities and were not acquired
in connection with or as a participant in any transaction having such purpose or
effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.

Date: March 8, 2002

By: /s/  Kevin E. O'Brien
Title: Chief Operating Officer